Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:05:32 EDT Sun 15 Mar 2026
Enter Symbol
or Name
USA
CA



Q:GILD - GILEAD SCIENCES INC - https://www.gilead.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GILD - Q0.3140.19·150.470.1144.99+0.600.44,375.7633,14245,275146.85  148.22  144.20157.27  93.3719:49:59Mar 0215 min RT 2¢

Recent Trades - Last 10 of 45275
Time ETExPriceChangeVolume
19:49:59Q145.07-0.145
19:49:59Q145.07-0.145
19:49:59Q145.07-0.145
19:49:59Q145.07-0.141
19:34:59Q145.07-0.145
19:34:59Q145.07-0.145
19:34:59Q145.07-0.145
19:34:59Q145.07-0.141
19:34:59Q145.07-0.144
19:34:59Q145.07-0.145

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-03-02 08:30U:GILDNews ReleaseGilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
2026-02-25 13:44U:GILDNews ReleaseGilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
2026-02-23 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conferences
2026-02-23 06:01U:GILDNews ReleaseGilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
2026-02-17 08:30U:GILDNews ReleaseGilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
2026-02-10 16:02U:GILDNews ReleaseGilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
2026-02-10 16:01U:GILDNews ReleaseGilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
2026-02-06 08:30U:GILDNews ReleaseFDA Approves Label Update for Kite's Yescarta(TM) for Relapsed/Refractory Primary Central Nervous System Lymphoma
2026-01-27 16:05U:GILDNews ReleaseGilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
2026-01-21 17:00U:GILDNews ReleaseNew England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy(TM) Plus Keytruda(TM) as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
2025-12-22 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conference
2025-12-22 08:00U:GILDNews ReleaseGilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
2025-12-19 14:21U:GILDNews ReleaseGilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
2025-12-18 08:30U:GILDNews ReleaseGilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
2025-12-15 08:30U:GILDNews ReleaseGilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
2025-12-12 10:31U:GILDNews ReleaseGI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
2025-12-09 08:30U:GILDNews ReleaseGilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
2025-12-07 08:00U:GILDNews ReleaseYescarta(TM) Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
2025-12-06 14:00U:GILDNews ReleaseKite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma